Parkinson Disease
Conditions
Brief summary
This study will collect data on various aspects of airway sensation and function, and determine how it relates to the development of swallowing and cough dysfunction in Parkinson's disease. Participants will be followed over a 3-year period, with once-per-year visits to collect the data.
Detailed description
Aspiration pneumonia (APn) occurs at a disproportionately hig rate in patients with Parkinson's disease (PD) versus healthy age-matched older adults. This is of particular public health concern given that aspiration pneumonia infection is a leading cause of death in persons with PD. The development of APn is multifactorial with aspiration of material from disordered swallowing (dysphagia) without proper cough response being the main contributing factor. These findings reflect the fact that both swallowing and cough are sensorimotor behaviors, and thus require appropriate detection and scaling of a sensory stimulus in order to produce an appropriate motor response. The long-term goal of this research is to advance the management of airway protection deficits in patients with neurodegenerative disease in order to decrease morbidity and mortality due to aspiration related lung infection. The objective here, which is a critical step in pursuit of that goal, is to further specify the sensory mechanisms associated with airway protection disorders in order to advance the clinical management of these patients. In order to accomplish the objective of this application the study team has identified 3 aims: First, determine relationship(s) between airway somatosensation, reflex cough and swallowing function in people with PD, and how these relationships may change with disease progression, over time. Second, determine whether cortical processing of sensory information is associated with deficits in reflex cough sensitivity or swallowing function in people with PD, and third, to determine how the central neural filtering of airway sensory stimuli may relate to the development of airway protective disorders. The study team will accomplish these aims in 2 experimental studies. First, the study team will test the magnitude of respiratory resistive loads, in people with PD across a range of disease durations, and in a healthy control group. The study team will measure reflex cough, using a cough-inducing irritant (capsaicin), and swallowing function. The study team will perform these tests at 3 time-points, spaced 10-14 months apart, in order to determine the relationships between respiratory sensation, cough sensitivity and effectiveness, and swallowing function, and how they change with advancing disease duration. Next the study team will perform electroencephalographic recordings time-locked to paired respiratory stimuli to determine cortical processing of airway sensory information. The study team will measure the amplitude and latency of the sensory evoked potential peaks, and compute ratios of peak amplitude between the first and second paired stimulus in order to determine the degree of sensory gating. The realization of the proposed aims and studies is significant because it is a necessary step in our program of research that is expected to lead to earlier, more accurate identification, as well as targeted interventions for airway protection deficits in PD. Completion of this research is systematically important for our goal of maintaining adequate airway protective function in PD patients; the results are expected to directly impact reductions in health care costs, morbidity, and mortality related to airway protection deficits.
Interventions
Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Between the ages of 45 and 85 years 2. Diagnosis of PD, Hoehn and Yahr stages I - IV, by a fellowship trained neurologist arriving at the diagnosis of PD by applying strict UK brain bank criteria (PD participants only)
Exclusion criteria
1. Neurological disorders other than PD (i.e., stroke, etc.) 2. Difficulty complying due to neuropsychological dysfunction (i.e., severe depression) 3. Allergy to capsaicin or hot peppers 4. History of head or neck cancer 5. History of smoking in the past 5 years 6. Any neurological disorder including PD (Healthy control group only)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory Sensitivity | 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit) | Slope of perception of resistive load and load resistance: Magnitude estimation of respiratory load (6 - no difficulty inhaling - 20 maximum difficulty inhaling) is plotted on the y-axis and respiratory load (0, 5, 10, 25 & 40 cm H2O loads) is plotted on the x-axis. The slope of the resulting regression line is the measure. |
| Urge to Cough Sensitivity | 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit) | Urge to cough sensitivity slope: Slope of the line created by plotting the urge to cough (0 indicating none - 10 indicating maximal) on the y-axis and capsaicin concentration (increasing from 0, 25, 50, 100, 200 micromolar) on the x-axis. |
| Penetration-aspiration Scale | 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit) | Rating of airway intrusion of bolus material during swallowing ranging from 1 (best, no airway invasion) to 8 (worst, silent aspiration). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cough Peak Flow Rate | 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit) | Highest airflow rate (in liters per second; L/s) during cough |
| Swallowing Timing | 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit) | Duration from bolus head passing mandible to laryngeal vestibule closure measured in frames. Data are collected at 33 frames per second. |
Countries
United States
Participant flow
Recruitment details
Participant recruitment began 12/2017 and ended 2/2022. Participants with Parkinson Disease (PD) were recruited from an IRB-approved clinical database of people with PD. Healthy (non-PD) participants were recruited using advertisement fliers and word-of-mouth. All participants were seen in research space at the outpatient Fixel Institute for Neurological Diseases at the University of Florida.
Participants by arm
| Arm | Count |
|---|---|
| Healthy Controls Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
Capsaicin: Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
Resistive respiratory loads: Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
Event-related evoked potential using electroencephalography (EEG).: The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
Fluoroscopic swallow evaluation: Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency. | 19 |
| Parkinson's Disease Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
Capsaicin: Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
Resistive respiratory loads: Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
Event-related evoked potential using electroencephalography (EEG).: The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
Fluoroscopic swallow evaluation: Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency. | 100 |
| Total | 119 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 22 |
| Overall Study | Withdrawal by Subject | 0 | 6 |
Baseline characteristics
| Characteristic | Healthy Controls | Parkinson's Disease | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 13 Participants | 71 Participants | 84 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants | 29 Participants | 35 Participants |
| Age, Continuous | 68.1 years STANDARD_DEVIATION 8.5 | 69.1 years STANDARD_DEVIATION 7.3 | 68.8 years STANDARD_DEVIATION 7.4 |
| Disease duration (PD only) 11 + years | — | 25 participants | 25 participants |
| Disease duration (PD only) 1 - 5 years | — | 49 participants | 49 participants |
| Disease duration (PD only) 6 - 10 years | — | 26 participants | 26 participants |
| Hoehn &Yahr score (PD only) | — | 2 units on a scale | 2 units on a scale |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment United States | 19 participants | 100 participants | 119 participants |
| Sex: Female, Male Female | 12 Participants | 27 Participants | 39 Participants |
| Sex: Female, Male Male | 7 Participants | 73 Participants | 80 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 19 | 0 / 100 |
| other Total, other adverse events | 0 / 19 | 0 / 100 |
| serious Total, serious adverse events | 0 / 19 | 0 / 100 |
Outcome results
Penetration-aspiration Scale
Rating of airway intrusion of bolus material during swallowing ranging from 1 (best, no airway invasion) to 8 (worst, silent aspiration).
Time frame: 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit)
Population: For the PD group, the numbers analyzed in years 2 and 3 of the study reflect loss of participants to either withdrawal or loss to follow up. In some cases fluoroscopy was not available in the year 2 or 3 visit, so some participants were not included due to no data for those visits. Not that on the Penetration-Aspiration scale used, higher numbers are worse, with the full range being 1 (normal swallow) to 8 (silent aspiration).
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Healthy Controls | Penetration-aspiration Scale | Year 1 | 1 score on a scale |
| Parkinson's Disease | Penetration-aspiration Scale | Year 1 | 2 score on a scale |
| Parkinson's Disease | Penetration-aspiration Scale | Year 2 (PD only) | 2 score on a scale |
| Parkinson's Disease | Penetration-aspiration Scale | Year 3 (PD only) | 2 score on a scale |
Respiratory Sensitivity
Slope of perception of resistive load and load resistance: Magnitude estimation of respiratory load (6 - no difficulty inhaling - 20 maximum difficulty inhaling) is plotted on the y-axis and respiratory load (0, 5, 10, 25 & 40 cm H2O loads) is plotted on the x-axis. The slope of the resulting regression line is the measure.
Time frame: 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit)
Population: The healthy control group had only 1 visit, whereas the PD group had 3 visits. Thus, the 2nd and 3rd rows in the outcome measure table are pertinent only to the PD participants. The numbers analyzed for the PD group in years 2 and 3 are smaller than year 1 due to participant withdrawals or loss to follow up.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy Controls | Respiratory Sensitivity | Year 1 visit | 0.22 scores on a scale / CmH2O | Standard Deviation 0.08 |
| Parkinson's Disease | Respiratory Sensitivity | Year 1 visit | 0.22 scores on a scale / CmH2O | Standard Deviation 0.07 |
| Parkinson's Disease | Respiratory Sensitivity | Year 2 visit (PD only) | 0.21 scores on a scale / CmH2O | Standard Deviation 0.07 |
| Parkinson's Disease | Respiratory Sensitivity | Year 3 visit (PD only) | 0.22 scores on a scale / CmH2O | Standard Deviation 0.06 |
Urge to Cough Sensitivity
Urge to cough sensitivity slope: Slope of the line created by plotting the urge to cough (0 indicating none - 10 indicating maximal) on the y-axis and capsaicin concentration (increasing from 0, 25, 50, 100, 200 micromolar) on the x-axis.
Time frame: 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit)
Population: For the PD group, the numbers analyzed in years 2 and 3 of the study reflect loss of participants to either withdrawal or loss to follow up.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy Controls | Urge to Cough Sensitivity | Year 1 | 0.31 scores on a scale / micromolar capsaicin | Standard Deviation 0.08 |
| Parkinson's Disease | Urge to Cough Sensitivity | Year 1 | 0.22 scores on a scale / micromolar capsaicin | Standard Deviation 0.08 |
| Parkinson's Disease | Urge to Cough Sensitivity | Year 2 (PD only) | 0.21 scores on a scale / micromolar capsaicin | Standard Deviation 0.09 |
| Parkinson's Disease | Urge to Cough Sensitivity | Year 3 (PD only) | 0.20 scores on a scale / micromolar capsaicin | Standard Deviation 0.09 |
Cough Peak Flow Rate
Highest airflow rate (in liters per second; L/s) during cough
Time frame: 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit)
Population: For the PD group, the numbers analyzed in years 2 and 3 of the study reflect loss of participants to either withdrawal or loss to follow up. The measure (L/s) is airflow - higher is better (indicating more airflow out per second), a measure of cough effectiveness.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy Controls | Cough Peak Flow Rate | Year 1 | 3.17 Liters of air per second (L/s) | Standard Deviation 1.31 |
| Parkinson's Disease | Cough Peak Flow Rate | Year 1 | 3.67 Liters of air per second (L/s) | Standard Deviation 1.31 |
| Parkinson's Disease | Cough Peak Flow Rate | Year 2 (PD only) | 3.27 Liters of air per second (L/s) | Standard Deviation 1.2 |
| Parkinson's Disease | Cough Peak Flow Rate | Year 3 (PD only) | 3.01 Liters of air per second (L/s) | Standard Deviation 1.18 |
Swallowing Timing
Duration from bolus head passing mandible to laryngeal vestibule closure measured in frames. Data are collected at 33 frames per second.
Time frame: 3 years, three time points (assessed at year 1 visit, year 2 visit, and year 3 visit)
Population: For the PD group, the numbers analyzed in years 2 and 3 of the study reflect loss of participants to either withdrawal or loss to follow up.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Healthy Controls | Swallowing Timing | Year 1 | 6.10 Frames | Standard Deviation 7.24 |
| Parkinson's Disease | Swallowing Timing | Year 3 (PD only) | 8.14 Frames | Standard Deviation 5.32 |
| Parkinson's Disease | Swallowing Timing | Year 1 | 6.70 Frames | Standard Deviation 10.22 |
| Parkinson's Disease | Swallowing Timing | Year 2 (PD only) | 8.85 Frames | Standard Deviation 6.63 |